is an aggressive malignancy that continuous to show increasing incidences in most countries of the world (1) . Intrinsic and environmental factors have an important influence on the individual risk for developing melanoma. Crucial intrinsic factors are the inherited skin color (degree of skin pigmentation) or, less frequently, mutated tumorsuppressor genes (e.g., CDKN2A, CDK4). Among the environmental melanoma risk factors the exposure to ultraviolet (UV) radiation is most important. The overall number of nevi largely depends on exposure to UV radiation in early childhood, and is one major predisposing risk indicator for the development of melanoma (2) . The risk to develop melanoma rises almost linearly with increasing numbers of nevi (3) .
Despite a much lower incidence of cutaneous melanoma compared to non-melanoma skin cancers, it causes the majority (approximately 90%) of skin cancer-related deaths. Melanoma thickness is an important prognostic factor, wherein more advanced tumors are strongly associated with an increased mortality rate (4) . Therefore, the early detection of melanoma at "in situ", or curable early invasive stages, is fundamental for the patients' survival.
As for now, the most frequently applied method for detecting melanoma is the visual inspection. The number of benign lesions excised to detect one melanoma (NNE, number needed to excise) may be viewed as a surrogate marker for the efficiency of melanoma screening. The NNE for melanoma is related to many factors, including the clinicians' experience as well as lesions' and patients' characteristics. The NNE varies in a broad range and ranges from 20 to 40 for general practitioners at nonspecialized clinics, 19-28 for general practitioners at skin cancer clinics, and down to four for dermatologists at specialized clinics (5, 6) . Therefore, to prevent unnecessary biopsies and ultimately reduce the costs of intensified screening efforts, it seems essential to design innovative, objective, and accurate diagnostic instruments as an aide for the screening physician.
Category-I Devices
Category-I devices are eligible for screening of patients in daily clinical routine, which implies, that many (if not all) lesions of a patient may be examined at an acceptable amount of time. The correct interpretation of examination results requires a considerable amount of training that needs to be refreshed and updated continuously (Table 1) .
Dermoscopy provides additional details derived from a microscopic level (Fig. 1a,b) including the architecture, the vascular structures, and the distribution of color across the lesion (7) . Dermoscopy significantly improves the preoperative diagnostic accuracy of cutaneous melanoma, which has been conclusively shown by two independent meta-analyses (8, 9) . In 1987, Pehamberger et al. (10) reported a first systematic analysis of dermoscopic patterns ("pattern analysis") in pigmented skin lesions. In the following years, a number of related algorithms (e.g., the ABCD rule of dermoscopy) were designed and validated in clinical studies (11) (12) (13) . In addition to an improved sensitivity, dermoscopy was shown to reduce unnecessary excisions of benign nevi (5, 14) . In recent decades, dermoscopy has become a routine examination technique for dermatologists in Europe and is gaining acceptance worldwide. Becoming an expert in dermoscopy requires extensive training, and results of a dermoscopic evaluation may vary with the experience of the clinician (15) .
Dramatic advances in imaging and computer hardware fueled the rapid integration of sequential digital dermoscopy (SDD) devices into the clinical setting. The electronic storage of digital overview, close-up, and dermoscopic images offered the chance for a side-by-side comparison during later examination of patients (7) . The basic assumption behind this dermoscopic follow-up strategy is that nevi remain stable, whereas melanomas tend to change over time (Fig. 2a,b) (16) . Numerous studies reported that SDD is effective in detecting early melanoma, especially in patients at increased melanoma risk who carry a high number of atypical nevi (17) (18) (19) (20) . In these patients, the comparison of dermoscopic baseline images with follow-up images is of great help for unmasking subtle dynamic changes that may indicate cutaneous melanoma (21, 22) . Atypical nodular lesions are not suitable for SDD follow-up, but should be excised immediately. More recently, a meta-analysis reported results of SDD follow-up for more than 52,000 melanocytic lesions and (24, 25) . Patient age is one important parameter to be considered before inclusion for total body photography. In younger patients (less than 50 years of age) only less than 1% of detected new lesions were histologically confirmed to be melanoma, whereas in older patients (over 50 years of age) 30% of new lesions were melanoma (26) . Total body photography may increase the sensitivity of melanoma detection when used as an adjunct to SDD (18, 25) . However, a decrease in biopsy rate (i.e., increased specificity) has not been conclusively demonstrated (27) .
Category-II Devices
Devices of category-II are not eligible for complete skin cancer screening examinations, but rather for the assessment of a restricted number of more atypical, preselected lesions. The reasons that speak against an application of these technologies to all lesions of a patient differ between the various devices and range from a low specificity, that may result in unnecessary excisions of many benign lesions, to timerequirements of up to 20 min for the analysis of just one lesion. The process of selecting the correct lesions for a deeper analysis with the category-II devices necessitates the knowledge of an experienced dermatologist, while the operation of the devices themselves requires only limited training. The results are presented in form of numerical diagnostic scores, which indicate the probability of malignancy. MelaFind (Strata Skin Sciences, Horsham, PA, USA) is a device intended for the computer-aided multispectral digital analysis of melanocytic lesions with at least one clinical or historical characteristic of cutaneous melanoma. The imaging system irradiates the skin with 10 spectral wavelengths from blue (430 nm) to near infrared (950 nm). An attached computer system analyses the spectrum of light reflected from within the tissue. MelaFind's proprietary computer algorithm then calculates the threedimensional morphological disorganization (e.g., asymmetry, color variation, texture changes) (28) and generates a diagnostic score that is backed-up by a melanoma probability derived from the positive predictive value of the pivotal study (Fig. 3a,b) . For many users a score ≥2, that is, associated with a melanoma probability of ≥6%, indicates a relevant risk that should trigger an excisional biopsy (29) . The registration study enrolled a total of 1831 lesions and a 98.4% sensitivity was reported (28) . However, the data published on MelaFind raised some concerns, especially regarding the low average specificity of 9.5% (30) . Importantly, in the setting of the registration study and later "reader studies" (31-33) only lesions that had already been selected for excision by dermatologist to rule out/confirm melanoma were enrolled. Therefore, published data may not represent the performance of MelaFind under real-life clinical conditions. Recently, a group of authors affiliated with the company of the device, presented limited data on its use in a dermatology outpatient setting (34) . More data attained from the application of MelaFind under real-life-conditions are eagerly awaited.
Electrical impedance spectroscopy (EIS) is able to detect changes in cell size, shape, orientation, compactness, and structure of cell membranes in skin tissue by applying an electrical alternating current. Pathogenic alterations in skin tissue may influence the ability of cells to conduct and store electricity, a measurable property known as electrical impedance (35) . The Swedish company SciBase developed the impedance spectroscopy system Nevisense, as a diagnostic tool for melanoma detection. After moisturizing the skin, a probe with an electrode and gold covered pins is pressed to the lesion of interest.
The electrode is able to measure a surface of approximately 5 9 5 mm. The proprietary computer algorithm of the device classifies the lesion in comparison to unaffected neighboring skin and calculates a score between 0 and 10, reflecting the degree of atypia identified (Fig. 4a,b) . Each score is backed-up by a melanoma probability-assessment and one complete measurement takes less than 10 s (35, 36) (37) . The observed sensitivity and specificity of the device in a pool of lesions recruited for excision were 96.6% and 34.4%, respectively. Recently, SciBase announced the results from their Reader Study, performed in the United States, in which 41 dermatologists reviewed 141 randomly selected lesions with a clinical suspicion of melanoma. The study showed that the availability of Nevisense measurements significantly improved the diagnostic performance of dermatologists in detecting melanoma, and was an important milestone to attain pre-market approval by the American FDA.
Raman spectroscopy uses laser light to change the vibrational state of molecular bonds. Photons that are scattered from a molecule have the same energy and wavelength as the incident photon (elastic scattering). Only a minor fraction of photons show a different and mostly lower wavelength, causing a shift in the light that is reflected back to a sensor. The plotting of transitions as a spectrum provides a "molecular fingerprint" that may be used to identify cancerous tissue (38) . Verisante Aura TM is an optical device using Laser Raman Spectroscopy technology and was developed by the British Columbia Cancer Agency and the University of British Columbia, Faculty of Medicine. The hardware includes a 785-nm laser that emits light transferred to a hand-held Raman probe via an optical fiber. The Raman probe will then collect the raw signal from a 3.5 mm diameter area of skin. The attached spectrometer performs the spectral analysis in less than 1 s. In a proof-of-concept clinical study performed in 2011, Raman spectroscopy was shown to have the capacity to classify and differentiate malignant from benign skin lesions. In this study, Raman spectra of 1022 skin lesions from 848 patients were assessed. The results published in 2012 showed sensitivities between 95% and 99% and specificities between 15% and 54% (38) . In Germany, Verisante Aura gained market access in 2011 and is licensed for the evaluation of skin lesions clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma.
Category-III Devices
These tools require extensive training for the correct interpretation of microscopic images and their purchase is associated with high costs. Therefore, category-III devices will mostly be located at specialized centers, where they can be operated by trained experts.
In vivo reflectance confocal microscopy (RCM), is a technology for the non-invasive imaging of skin tissue in real time and at a near-histopathological resolution. In the past decade, multiple studies have evaluated the use of RCM for the diagnosis of melanoma. The RCM device illuminates the tissue via a point laser light source. Reflected light that is emitted from distinct skin structures, of which melanin provides the strongest signal, allows for the morphologic evaluation of skin lesions (39) (40) (41) . Specific patterns for the RCM-based differentiation of nevi and melanoma have been described (Fig. 5a-c) . For the assessment of larger skin areas (up to 8 9 8 mm), the RCM device uses a scanning mode that offers a view on horizontal sections at different skin levels down to the papillary dermis. To implement a broader application of RCM in the clinical setting, a consensus for terminology in RCM has been published (42) . For the differentiation of melanoma from nevi, two different algorithms have been developed showing similar sensitivity and specificity values for several RCM criteria (43, 44) . The two-step method developed by Segura et al. (44) uses a number of criteria not indicating melanoma (protective) as well as RCM features indicating melanoma. In general, the presence of two or more melanoma associated features resulted in a sensitivity of 86.1% and a specificity of 95.3% for the diagnosis of melanoma. Pellacani et al. identified six criteria, two major and four minor criteria, which were independently correlated with a melanoma diagnosis (43) . The presence of at least two features, one major and one minor criterion, was essential for melanoma diagnosis. On the other hand, an unremarkable dermo-epidermal architecture and the absence of a pagetoid infiltration as well as atypical cells were indicative of benign lesions. Of note, the interpretation of RCM images requires extensive training and results may vary with the experience of the examining physician.
In vivo multiphoton tomography is a non-invasive technique for the evaluation of cellular and extracellular structures at ultra-high subcellular resolution. The system uses a femtosecond laser beam with two or more long-wave, low-energy photons for excitation of all naturally occurring, endogenous fluorescent molecules such as NAD(P)H [reduced form of nicotinamide adenine dinucleotide (phosphate)], flavins, porphyrins, and melanin. The extracellular matrix element collagen is imaged by inducing second harmonic generation, a non-fluorescence process, that occurs when two-photons interact with collagen fibers by emitting a single photon at twice the original energy (i.e., at half the excitation wavelength). Autofluorescence and second harmonic generation signals are recorded by detectors. Recent publications showed that the classification of a lesion as melanoma could be based on the presence of atypical, large, short-lifetime cells in the upper layers in combination with an architectural disorder (45) . Images at various depths were generated by sequentially modifying the depth of the focus plane in the tissue reaching levels of up to 200 mm. JenLab GmbH (Jena, Germany) developed the first in vivo multiphoton tomograph for human skin, the CE-marked medical device DermaInspect â (Jenlab GmbH, Jena, Germany). A retrospective observational ex vivo study evaluated the multiphoton laser tomography combined with fluorescence lifetime imaging. Sensitivity and specificity values for melanoma diagnosis were 100% and 98%, respectively (45) . In the first clinical in vivo study using DermaInspect, sensitivity values up to 95% and specificity values up to 97% were reported for diagnostic classification. The mostsignificant diagnostic criteria were the architectural disarray of the epidermis, poorly defined keratinocyte cell borders as well as the presence of pleomorphic or dendritic cells (46) . Fig. 4 . Nevisence analysis of a pigmented lesion on the upper arm of a 27-year-old woman. The clinical image shows a pigmented lesion of roundish shape and variegated brownish colors (a). Dermoscopy shows a small brownish lesion with 4 mm in diameter and darker brown pigmentation at the center extending to the lower boarder (b). There are no distinct clues for melanoma. The electrical impedance spectroscopy (EIS) analysis resulted in a score of three, which was associated with a 98% probability of a benign lesion (negative predictive value) in the Nevisence pivotal study (c). Histopathology in this case confirmed a benign melanocytic nevus. [Colour figure can be viewed at wileyonlinelibrary.com].
Category-IV Devices
Devices of this category are still at a more experimental stage of development or at the brink of entering the clinical arena.
Stepwise two-photon-laser spectroscopy excites autofluorescence spectra of melanin without overwhelming background fluorescence from other endogenous skin fluorophores. LTB-Lasertechnik Berlin developed the LIMES 16-P device that was shown to discriminate the fluorescence of different endogenous fluorophores in favor of melanin. Melanin is excited by stepwise twophoton nanosecond pulses at a wavelength of 810 nm from a dye laser. This mode of excitation was found to be unique for melanin and the generated fluorescence is measured by a sensitive photon detector. When comparing the fluorescence spectra of normal skin, melanocytic nevi, and melanoma, distinctly different spectral shapes were found. Differences in the fluorescence spectra are probably cause by changes in melanogenesis and different contents of eumelanin and pheomelanin (47) (48) (49) (50) . The occurrence of a 640 nm peak-intensity fluorescence may be viewed as a fingerprint spectrum for melanoma. In an ex vivo proof-of-concept study, 167 melanocytic nevi and melanomas were examined and a sensitivity of 93.5% and a specificity of 80.1% were reported (47) . Lately, the stepwise two-photon-laser spectroscopy technology was transferred to Magnosco GmbH and will be further developed for market entry. First prototypes intended for clinical use (Magnosco Dermatofluoroscope DFC 1) are currently under evaluation as part of a prospective multicenter clinical registration study (Fig. 6a-d) . First results are expected at the end of 2016.
Quantitative Dynamic Infrared Imaging is a technology based on the detection of electromagnetic radiation emitted by the skin in the infrared domain. The amount of emitted radiation depends on skin temperature (51, 52) . Many malignant skin neoplasms and especially melanoma differ from healthy tissue in terms of heat generation and blood supply due to an increase in metabolic rate, neoangiogenesis, and inflammation (53). Herman et al. (54) developed a highly sensitive thermographic imaging system that allows accurate measurements of transient skin-surface temperature distributions. As a prerequisite of this technology a standardized cooling stress needs to be applied to the skin, first. A significant difference in temperature between melanoma lesions and healthy tissue during thermal recovery was reported. Experimental data confirmed that more advanced melanomas are associated with a more pronounced temperature difference in comparison to healthy tissue (55).
Due to the rapid development of advanced sensors at ever decreasing costs, thermal imaging seems a promising approach (56) . Scientists from DERMOLOCKIN GmbH, a spin-off company of the Zurich University of Applied Sciences, initiated a next evolutionary step by developing a prototype that uses a periodic thermal stimulation of the skin surface. Compared to previous approaches, this new methodology revealed an improved sensitivity coupled with a higher spatial resolution (57) . The initiation of clinical studies is expected in 2016.
Conclusion
Detection and excision of cutaneous melanoma at early and still curable stages is an effective strategy to further reduce skin cancer mortality rates. In addition to the clinical assessment with the unaided eye, only a few examination strategies allow for a true screening of the whole integument, namely dermoscopy, sequential digital dermoscopy, and total body photography. All remaining devices discussed in this article are intended for application on preselected melanocytic lesions to facilitate the decision for or against excisional biopsy. Multispectral imaging (MelaFind), electrical impedance spectroscopy (Nevisence), and Raman spectroscopy (Verisante Aura) have received approval for clinical use and may be applied by dermatologists familiar with skin cancer screening. In contrast, the reading and diagnostic interpretation of images derived from reflectance confocal microscopy (VivaScope) or multiphoton spectroscopy (DermaInspect) require extensive training comparable to training periods of histopathologists.
Technologies that have not yet entered the clinical arena are the stepwise two-photon-laser spectroscopy and quantitative dynamic infrared imaging. Above all, it has to be emphasized that none of the aforementioned examination techniques are currently able to provide a definite and final diagnosis or to completely replace the histopathological examination of excisional biopsies.
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